Abstract Library

#1837 Evaluation of Faecal Elastase 1 in Symptomatic Patients with Neuroendocrine Tumours

Introduction: There is limited data on exocrine pancreatic insufficiency in patients on somatostatin analogues(SSA) which affects quality of life in NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Khan M

Authors: Chaudhry R, Newbould R, Williams M, Reid K, Donnelly L,

Keywords: Quality of life, Steatorrhoea, Diarrhea, SST,

#1835 A Prospective Service Evaluation of Systematic Gastroenterological Assessment and Management on Patients with Neuroendocrine Tumours in South East Wales

Introduction: Patients with NETs can experience gastrointestinal(GI) symptoms including diarrhoea, steatorrhoea and urgency.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Donnelly L, Tailor S, Reid K, Williams M, Lewis J,

Keywords: Quality of life, Diarrhea,

#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D,

Keywords: Lung NETs, lanreotide,

#1504 Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs

Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Reidy-Lagunes D

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Mirakhur B, Massien C,

Keywords: Lung NETs, lanreotide,

#1470 Exploring Gastrointestinal Symptoms And Their Impact on Quality of Life in Patients with Neuroendocrine Tumours

Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Williams M, Reid K, Ng S, Benny A, Lewis J,

Keywords: Quality of life, symptoms,